SDZNY or ZTS: Which Is the Better Value Stock Right Now?

Zacks analysis identifies Sandoz Group AG (SDZNY) as a superior value stock compared to Zoetis (ZTS) within the Medical - Drugs sector, despite both holding a Zacks Rank #2 (Buy) for strong earnings outlooks. SDZNY exhibits more attractive valuation metrics, including a forward P/E of 18.41, PEG ratio of 1.02, and P/B ratio of 2.92, significantly lower than ZTS's respective figures of 22.64, 2.31, and 12.8, leading to a B Value grade for SDZNY versus C for ZTS.

Analysis

Within the Medical - Drugs sector, both Sandoz Group AG (SDZNY) and Zoetis (ZTS) exhibit strong earnings outlooks, as indicated by their shared Zacks Rank of #2 (Buy) which is driven by positive earnings estimate revisions. However, a quantitative value assessment reveals a significant divergence between the two. SDZNY presents a more attractive valuation profile, trading at a forward P/E of 18.41 versus 22.64 for ZTS. This valuation advantage is further supported by SDZNY's PEG ratio of 1.02, suggesting a price more reasonably aligned with its earnings growth expectations compared to ZTS's PEG of 2.31. The disparity is most pronounced in the price-to-book metric, where SDZNY's P/B of 2.92 is substantially lower than ZTS's 12.8. These metrics culminate in a superior Zacks Value grade of 'B' for SDZNY, compared to a 'C' for ZTS, positioning Sandoz as the more compelling value-oriented investment between the two based on this analysis.

Key Decisions for Investors

• Value-focused investors should consider Sandoz Group (SDZNY) as a more attractive entry point in the medical drugs sector, given its favorable valuation metrics relative to its positive earnings outlook.
• While Zoetis (ZTS) maintains a positive earnings outlook, its premium valuation, particularly its P/E of 22.64 and P/B of 12.8, warrants caution and requires confidence in its ability to deliver superior growth to justify the current price.
• For portfolios with exposure to the sector, this analysis suggests a potential pair trade or a re-weighting from ZTS to SDZNY to capitalize on the apparent valuation disconnect, while monitoring for any changes to the earnings estimate revisions that underpin the current 'Buy' ratings.